Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Lee YC, et al. Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10. Eur J Cancer. 2017. PMID: 28802188
Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.
Lee YC, Jivraj N, O'Brien C, Chawla T, Shlomovitz E, Buchanan S, Lau J, Croke J, Allard JP, Dhar P, Laframboise S, Ferguson SE, Dhani N, Butler M, Ng P, Stuart-McEwan T, Savage P, Tinker L, Oza AM, Lheureux S. Lee YC, et al. Obstet Gynecol Int. 2018 May 17;2018:1867238. doi: 10.1155/2018/1867238. eCollection 2018. Obstet Gynecol Int. 2018. PMID: 29887891 Free PMC article. Review.
Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer.
Lee YC, Jivraj N, Wang L, Chawla T, Lau J, Croke J, Allard JP, Stuart-McEwan T, Nathwani K, Bowering V, Karakasis K, O'Brien C, Shlomovitz E, Ferguson SE, Buchanan S, Ng P, Cyriac S, Tinker L, Dhani N, Oza AM, Lheureux S. Lee YC, et al. J Oncol Pract. 2019 Dec;15(12):e1066-e1075. doi: 10.1200/JOP.18.00793. Epub 2019 Sep 24. J Oncol Pract. 2019. PMID: 31550202 Free PMC article.
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM. Lheureux S, et al. Among authors: lee yc. Clin Cancer Res. 2020 Aug 15;26(16):4206-4215. doi: 10.1158/1078-0432.CCR-19-4121. Epub 2020 May 22. Clin Cancer Res. 2020. PMID: 32444417 Clinical Trial.
Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
Madariaga A, Garg S, Bruce JP, Thiryayi S, Mandilaras V, Rath P, Oza AM, Dhani NC, Cescon DW, Lee YC, Chen E, Wang L, Clarke B, Lheureux S. Madariaga A, et al. Among authors: lee yc. Gynecol Oncol. 2020 Nov;159(2):539-545. doi: 10.1016/j.ygyno.2020.08.032. Epub 2020 Sep 8. Gynecol Oncol. 2020. PMID: 32912664
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML; GCIG Symptom Benefit Group. Lee YC, et al. Int J Gynecol Cancer. 2022 Jun 6;32(6):761-768. doi: 10.1136/ijgc-2021-003142. Int J Gynecol Cancer. 2022. PMID: 35086926 Free PMC article.
Interobserver and intraobserver variability of RECIST assessment in ovarian cancer.
Krasovitsky M, Lee YC, Sim HW, Chawla T, Moore H, Moses D, Baker L, Mandel C, Kielar A, Hartery A, O'Malley M, Friedlander M, Oza AM, Wang L, Lheureux S, Wilson M. Krasovitsky M, et al. Among authors: lee yc. Int J Gynecol Cancer. 2022 May 3;32(5):656-661. doi: 10.1136/ijgc-2021-003319. Int J Gynecol Cancer. 2022. PMID: 35379690
5,490 results